Heartflow 2025 Q2 Earnings 68.7% Drop in Loss Per Share

Heartflow (HTFL) reported its fiscal 2025 Q2 earnings on Sep 19th, 2025. The company delivered better-than-expected results, with a significant improvement in profitability. The 68.7% reduction in per-share loss and 60.7% narrowing in net loss highlight meaningful progress, even as the company continues to reinvest in growth initiatives.

Revenue
Heartflow's total revenue surged 39.8% year-over-year to $43.42 million in Q2 2025 from $31.05 million in Q2 2024, reflecting strong demand for its diagnostic offerings.

Earnings/Net Income
Heartflow reduced its loss per share to $1.46 in Q2 2025 from $4.66 in Q2 2024, a 68.7% improvement. The company also narrowed its net loss to $-9.20 million, a 60.7% decrease from the $-23.38 million net loss in the prior-year period. This indicates a meaningful improvement in financial performance and operational efficiency.

Price Action
Heartflow's stock edged up 1.48% on the latest trading day, but declined 1.50% during the most recent full trading week. However, it has gained 7.21% month-to-date, showing positive investor sentiment despite short-term volatility.

Post Earnings Price Action Review
Despite a narrowing of losses and strong revenue growth, Heartflow's stock has shown mixed performance in the short term. While it has posted a solid month-to-date gain, weekly performance was slightly negative, indicating market uncertainty or cautious sentiment around the company’s long-term profitability. The stock remains in a range-bound pattern with investors likely weighing the company’s continued reinvestment in product integration and procedural efficiency initiatives.

CEO Commentary
CEO Rob Mauck highlighted the company’s strong cash position and recent IPO as key enablers of growth. He emphasized the integration of Heartflow PCI Planner as a strategic move to enhance procedural efficiency and improve patient care. While acknowledging a shift in revenue mix toward lower average sales prices, Mauck expressed confidence in long-term value creation through expanded product applicability and clinical insights.

Guidance
Heartflow stated that its current cash and IPO proceeds will fund operations for at least the next 12 months. The company did not provide specific quantitative guidance for revenue or EPS, but reiterated a focus on procedural efficiency and product integration as key growth drivers.

Additional News
In the three weeks following the earnings release, Heartflow announced the closing of its upsized IPO on August 11, 2025, issuing 19.166 million shares at $21.00 per share. This followed a July 22 announcement that UnitedHealthcare will now cover Heartflow Plaque Analysis nationwide, marking a major milestone in reimbursement access. Additionally, the company unveiled landmark DECIDE Registry data on July 17, showing over 50% of patients had treatment changes after Heartflow Plaque Analysis, underscoring its clinical impact. These developments highlight Heartflow's growing market adoption and regulatory progress.